本帖最后由 老马 于 2012-1-13 21:20 编辑 ( |' q8 u$ k: N- F' o7 Y
4 {8 O q9 W# e3 B2 t! J爱必妥和阿瓦斯丁的比较9 C, K X) P o+ _. N; E
t3 {# y: ?4 B7 [0 R
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/ a8 `& ^ ?) ~5 Z4 e
& y/ u2 D9 @, o2 |
) \: t* G- i' |' h3 m) G/ _ I
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/( s1 [# A! y8 n9 d9 ]( o0 a/ r
==================================================
4 U V( m4 p* k2 gOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)6 J" y' L8 l9 {' s" p+ K/ a$ G
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
5 U9 U' [/ [3 Y2 x% h. F2 s: z, b, s/ h; pResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
+ R `' n e2 _/ o& J0 |/ t1 i
|